Tue.May 06, 2025

article thumbnail

Treating OUD With Buprenorphine Improves Pregnancy Outcomes

Drug Topics

Among patients treated with buprenorphine, 25.4% experienced adverse pregnancy outcomes, compared to 30.8% in the untreated group.

315
315
article thumbnail

Opinion: How to stop the shift of drug discovery from the U.S. to China

STAT

Five years ago, U.S. pharmaceutical companies didn’t license any new drugs from China. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers sending their business to China? As in many other industries, it’s so much cheaper to synthesize new compounds inside Chinese biotechnology firms once a novel biological target has been discovered in American laboratories.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

E-Prescribing Can Help Improve Prescriber, Pharmacist Collaboration

Drug Topics

The use of electronic prescribing can also bridge the gap in clinical history, which can help pharmacists be aware of adverse drug reactions and medication interactions.

315
315
article thumbnail

On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

PharmaVoice

Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

147
147
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Dispensing Leadership: Finding Solutions

Drug Topics

In this episode of the podcast, Shawn and Jesse discuss how every situation has a solution and the best way to find it.

247
247
article thumbnail

STAT+: Vinay Prasad tapped to run FDA center that regulates vaccines, gene therapies

STAT

WASHINGTON — Vinay Prasad, an academic and fierce critic of the medical mainstream, will be the next director of the Food and Drug Administration center that oversees the regulation of vaccines, gene therapies, and the blood supply.  Prasad, previously an epidemiology professor at the University of California, San Francisco, has sharply criticized the FDA in the past, including the Center for Biologics Evaluation and Research, the unit he will now lead.

Vaccines 145

More Trending

article thumbnail

Opinion: The entire U.S. health care system must be torn down and rebuilt

STAT

In “ We’ve Got You Covered ,” Liran Einav and Amy Finkelstein describe America’s existing patchwork of health care payment arrangements as a “teardown.” I agree. I support downsizing the Department of Health and Human Services (HHS), eliminating many programs, rolling back regulations , and creating a new system modeled on Social Security that will be simpler, less administratively burdensome, more affordable, and more effective at improving Americans&#x

Insurance 136
article thumbnail

7 benefits of zinc

The Checkup by Singlecare

Zinc is an essential nutrient for many bodily processes, such as immune function and wound healing. Your body doesnt naturally produce it, so you must consume it in the foods you eat or take a supplement to avoid a zinc deficiency. Luckily, many foods you probably already eat are chock-full of zinc, including seafood, red meat, poultry, whole grains, and legumes.

article thumbnail

Recursion cuts nearly half of its pipeline

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, there’s been a lot of discussion lately about how the U.S. can stay competitive in science, biomedical innovation, and drug development. We’ve got several pieces of news relevant to that issue today.

109
109
article thumbnail

Eli Lilly signs $415m deal for Alchemab’s ALS therapy  

Pharmaceutical Technology

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

91
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Research disrupted at the NIH Clinical Center

STAT

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Good morning, I’m back! It seems like there was a lot of news while I was away … drop me a line at theresa.gaffney@statnews.com to let me know the biggest stories I missed.

122
122
article thumbnail

Psilocybin at the Crossroads: Regulatory Barriers and the Pharmacist’s Role in Palliative Innovation

Pharmacy Times

Abigail Thomas, PharmD, and Lee A. Kral, PharmD, discuss the evolving role of psilocybin-assisted therapy in palliative care, highlighting current evidence, safety concerns, and how pharmacists can guide patient selection, manage drug interactions, and support education as the therapy moves closer to clinical use.

80
article thumbnail

Google’s Dr. Karen says farewell

STAT

Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Google’s chief health officer Karen DeSalvo announced she will retire this summer. DeSalvo, who likes to introduce herself as Dr.

Cerner 102
article thumbnail

Lilly forges a $415m ALS alliance with UK biotech Alchemab

pharmaphorum

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients

71
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

NEW ORLEANSIn the face of economic uncertainty, health system executives and venture capitalists are setting a high bar for digital health and artificial intelligence investments.

78
article thumbnail

PTC's Huntington study was positive. Why did its stock fall?

pharmaphorum

A potentially pivotal trial PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data

66
article thumbnail

Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy

PharmExec

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

52
article thumbnail

EU joins the bid to court beleaguered US scientists

pharmaphorum

The EU has announced a 500m to convince top scientific talent from around the world to relocate to Europe's "free and open" research environment

59
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Overcoming challenges in orphan drug development: From clinical trials to market

Pharmaceutical Technology

Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To rise to these challenges, the biopharma industry continues to develop innovative strategies to bring vital therapies swiftly to rare disease patients.

52
article thumbnail

Pharma Industry Outlook: Trends Shaping the Future

Pharma Marketing Network

The pharma industry is undergoing a seismic transformation. As 2025 unfolds, traditional business models are giving way to data-driven innovation, personalized care, and integrated digital ecosystems. Stakeholders across the healthcare spectrum must not only adapt to changethey must anticipate it. Imagine steering a ship through unpredictable currents.

FDA 52
article thumbnail

Recursion axes drug programmes to streamline pipeline  

Pharmaceutical Technology

Recursion Pharmaceuticals has narrowed its drug development pipeline as it seeks to reduce costs and reprioritise resources.

59
article thumbnail

Co-developing companion diagnostics to connect patients with emerging therapies

pharmaphorum

Incorporating NGS technology early in the drug development process lays the foundation for CDx development, and taking a co-development approach helps ensure patients have access to emerging therapies as soon as they are approved, positively impacting cancer patient outcomes while minimising the risks from inappropriate treatment.

52
article thumbnail

Investigational CAR T-Cell Therapy BCB-276 Receives Breakthrough Designation for Pediatric Patients Wirh DIPG

Pharmacy Times

The agent targets B7-H3, a commonly overexpressed protein in diffuse intrinsic pontine glioma (DIPG).

112
112
article thumbnail

Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy

Pharmaceutical Commerce

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

52
article thumbnail

Asembia 2025: Tracking Long-Term Outcomes Key to Advanced Therapy Value

PharmExec

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies and support future payment strategies.

52
article thumbnail

The ins and outs of HEOR – A lever for global health

pharmaphorum

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rob Abbott, CEO and executive director of ISPOR the leading professional society for HEOR globally about the ins and outs and trends of HEOR.

59
article thumbnail

Patient Services: A Marathon, Not A Sprint

PharmExec

Rob Truckenmiller, CEO of PharmaCord, talks about the companys role in patient services, trends he sees shaping patient access to healthcare in the U.S., and a recent patient-centric merger.

52
article thumbnail

How the Rise in Self-Injectables Is Impacting Pharmaceutical Manufacturing

Pharmaceutical Commerce

As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders become more prevalent, self-injectables are here to stay.

52
article thumbnail

Lilly Bolsters ALS Pipeline Through $415 Million Licensing Agreement with Alchemab Therapeutics

PharmExec

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly will assume responsibility for further development and commercialization of the novel platform.

52
article thumbnail

Pharma M&A deal value surges by 101% QoQ in Q1 2025 despite US political turbulence

Pharmaceutical Technology

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) of 2025 from $18.8bn in Q4 2024 to $37.7bn, according to leading data and analytics company GlobalDatas Pharmaceutical Intelligence Center Deals Database.

52
article thumbnail

Drug-Drug interactions : keep it up with challenges

Pharma Tutor

Drug-Drug interactions : keep it up with challenges admin Tue, 05/06/2025 - 16:08 Drug-Drug interactions are identified through a combination of clinical observation, scientific research, pharmacological knowledge, and the use of specialized tools. In clinical practice, healthcare providers assess the risk of interactions by reviewing a patients complete medication list, including prescription drugs, over-the-counter products, and supplements.

52
article thumbnail

Asembia 2025: Tracking Long-Term Outcomes Key to Advanced Therapy Value

Pharmaceutical Commerce

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies and support future payment strategies.

52
article thumbnail

FDA Issues Refusal to File for ImmunityBio’s sBLA for Anktiva in BCG-Unresponsive NMIBC

PharmExec

The Refusal to File letter comes despite the FDAs prior encouragement to submit a supplemental biologics license application for Anktiva in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.

FDA 52